Alnylam Pharmaceuticals, Inc. revenue by segment ALNY

Annual Quarterly

Alnylam Pharmaceuticals, Inc. splits its revenue into 7 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Amvuttra at $1.1 billion, 78% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	5,013	1,458	1,291	1,097	1,249	774	594	593	501
Amvuttra	3,859 +117.5% share 77.0%	1,130 +64.9% share 77.5%	1,012 +105.7% share 78.4%	827 +188.5% share 75.3%	685 share 54.9%	492 share 63.6%	310 share 52.2%	287 share 48.3%	—
TTR	—	—	—	—	—	—	—	—	309 share 61.7%
Royalty	277 +86.9% share 5.5%	95 +104.9% share 6.5%	72 +79.3% share 5.6%	61 +73.4% share 5.6%	46 +97.6% share 3.7%	40 share 5.2%	26 share 4.5%	35 share 6.0%	23 share 4.7%
GIVLAARI	340 +18.9% share 6.8%	89 +21.1% share 6.1%	—	87 +34.3% share 7.9%	74 +4.0% share 5.9%	81 share 10.4%	67 share 11.3%	65 share 10.9%	71 share 14.2%
OXLUMO	206 +10.9% share 4.1%	52 -0.6% share 3.6%	52 +11.2% share 4.0%	50 +13.9% share 4.5%	53 +31.4% share 4.2%	47 share 6.1%	42 share 7.1%	44 share 7.3%	40 share 8.0%
Collaborations	—	—	47 -23.3% share 3.7%	41 -61.7% share 3.7%	352 +512.9% share 28.2%	61 share 7.9%	99 share 16.7%	107 share 18.0%	57 share 11.5%
ONPATTRO	90 -54.2% share 1.8%	20 -49.9% share 1.3%	18 -64.9% share 1.4%	32 -43.5% share 2.9%	39 -22.3% share 3.1%	53 share 6.8%	49 share 8.3%	56 share 9.5%	50 share 10.0%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ALNY (Nasdaq)
Fiscal year ends: December 31
Headquarters: Cambridge, MA
SEC filer status: Large accelerated filer
SEC CIK: 1178670
Former names: ALNYLAM PHARMACEUTICALS INC (until Jul 2, 2004)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.